Cited by 269Alzheimer's disease research and treatmentsNeuroinflammation and Neurodegeneration MechanismsS100 Proteins and Annexins

In vivo and in vitro evidence supporting a role for the inflammatory cytokine interleukin-1 as a driving force in Alzheimer pathogenesis

Open access
Sheng, Jin G., Ito, Kazuhiro, Skinner, Robert D., Mrak, Robert E., Rovnaghi, Cynthia R., van Eldik, Linda J., Griffin, W.Sue T.·1996·Neurobiology of Aging

Abstract

Interleukin-1 (IL-1), an inflammatory cytokine overexpressed in the neuritic plaques of Alzheimer's disease, activates astrocytes and enhances production and processing of beta-amyloid precursor protein (beta-APP). Activated astrocytes, overexpressing S100 beta, are a prominent feature of these neuritic plaques, and the neurite growth-promoting properties of S100 beta have been implicated in the formation of dystrophic neurites overexpressing beta-APP in neuritic plaques. These facts collectively suggest that elevated levels of the inflammatory cytokine IL-1 drive S100 beta and beta-APP overexpression and dystrophic neurite formation in Alzheimer's disease. To more directly assess this driver potential for IL-1, we analyzed IL-1 induction of S100 beta expression in vivo and in vitro, and of beta-APP expression in vivo. Synthetic IL-1 beta was injected into the right cerebral hemispheres of 13 rats. Nine additional rats were injected with phosphate-buffered saline, and seven rats served as uninjected controls. The number of astrocytes expressing detectable levels of S100 beta in tissue sections from IL-1-injected brains was 1.5 fold that of either control group (p < 0.01), while tissue S100 beta levels were approximately threefold that of controls (p < 0.05). The tissue levels of two beta-APP isoforms (approximately 130 and 135 kDa) were also significantly elevated in IL-1-injected brains (p < 0.05). C6 glioma cells, treated in vitro for 24 h with either IL-1 beta or IL-1 alpha, showed significant increases in both S100 beta and S100 beta mRNA levels. These results provide evidence that IL-1 upregulates both S100 beta and beta-APP expression, in vivo and vitro, and support the idea that overexpression of IL-1 in Alzheimer's disease drives astrocytic overexpression of S100 beta, favoring the growth of dystrophic neurites necessary for evolution of diffuse amyloid deposits into neuritic beta-amyloid plaques.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/0197-4580(96)00104-2

Cites

32 of 32 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 3

  1. [3]Baggott PJ, Sheng JG, Cork L, Del Bigio MR, Brumback RA, Roberts GW, Mrak RE, Griffin WST. Expression of Alzheimer’s disease (AD)-related proteins during development in Down’s syndrome. Neurosci Soc Abstr. 1993;19:182. [Google Scholar]
  2. [17]Griffin WST, Stanley LC, Yeralan O, Rovnaghi CR, Marshak DR. Methods for the study of cytokines in human neurodegenerative disease. Methods Neurosci. 1993;17:268–287. [Google Scholar]
  3. [18]Marshak DR. S100β as a neurotrophic factor. Prog Brain Res. 1990;86:169–181. [PubMed] [Google Scholar]

Cited by

Sorted by citations

Authors
Sheng, J. G., Ito, K., Skinner, R. D., Mrak, R. E., Rovnaghi, C. R., van Eldik, L. J., & Griffin, W. S. T.
Affiliations
Northwestern University (US)
Corresponding author
Griffin, W.Sue T.
Venue
Neurobiology of Aging
Publisher
Elsevier BV
Published
1996-09
Volume
17
Issue
5
Pages
761-766
ISSN
0197-4580 (ISSN-L)
OpenAlex
W1994394172
Cited by
269
References
32
Citations by year
2026: 3 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 4 · 2021: 9 · 2020: 11 · 2019: 7 · 2018: 6 · 2017: 6 · 2016: 8 · 2015: 8 · 2014: 7 · 2013: 11 · 2012: 10
FWCI
8.09
Type
journal article
Language
en
Open access
Locations
  • Neurobiology of Aging (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • National Institutes of Health (1r01ns027414-01a1, 5p01ag010208-05)
  • National Institute on Aging (AG 10208, AG 12411, P01AG012411)
  • National Institute of Neurological Disorders and Stroke (NS27414)
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › S100 Proteins and Annexins
Keywords
interleukin-1, Alzheimer's disease, S100β, amyloid precursor protein, astrocytes, neuritic plaques, dystrophic neurites, neuroinflammation, IL-1β, IL-1α, C6 glioma cells, amyloid plaques
MeSH terms
Alzheimer Disease, Animals, Astrocytes, Brain Chemistry, Brain Neoplasms, Glioma, Humans, Immunohistochemistry, Interleukin-1, S100 Proteins, Tumor Cells, Cultured, Blotting, Northern, Blotting, Western, Up-Regulation, Amyloid beta-Protein Precursor, Rats, Sprague-Dawley, In Situ Hybridization, Rats

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review